A substance should only be included in the list as a ‘substance bringing added clinical benefit’ where it provides a clinically relevant advantage based on improved efficacy or safety or a major contribution to treatment. This may be the result, inter alia, of different modes of actions, different pharmacokinetic or pharmacodynamic profiles, different lengths of treatment or different routes of administration.
Recital 3, Commission Regulation (EU) No 122/2013 of 12 February 2013 amending Regulation (EC) No 1…
In forcesince 12 Feb 2013